GB1493941A - Pharmaceutical product for treatment of all leukaemia forms and neurotic syndromes - Google Patents

Pharmaceutical product for treatment of all leukaemia forms and neurotic syndromes

Info

Publication number
GB1493941A
GB1493941A GB33039/74A GB3303974A GB1493941A GB 1493941 A GB1493941 A GB 1493941A GB 33039/74 A GB33039/74 A GB 33039/74A GB 3303974 A GB3303974 A GB 3303974A GB 1493941 A GB1493941 A GB 1493941A
Authority
GB
United Kingdom
Prior art keywords
indole
treatment
tryptamine
aminoethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB33039/74A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB1493941A publication Critical patent/GB1493941A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

N-Acetyl-5-methoxy-tryptamine is obtained, starting from indigo, by the following reactions: (a) dry distillation of indigo mixed with zinc powder, to obtain indole; (b) conversion of the indole to 5-hydroxy-indole by treating the former with methanol in water and in the presence of ferric chloride; (c) converting the 5-hydroxy-indole to 3-(2-aminoethyl)-5-hydroxy-indole by treatment of the former with 2-amino-1-chloroethane in the presence of ethyl acetate and iron filings; (d) treating the product obtained from item (c) with dimethyl sulphate at a temperature not exceeding 25 DEG C; and (e) treating the (2-aminoethyl)-5-oxymethyl-indole, obtained under (d), with acetyl chloride at a temperature not exceeding 10 DEG C. The novel compound obtained is effective in the treatment of leucoses in their various forms. Its action can be boosted if it is used in combination with one of its derivatives, such as 5-methoxy-tryptamine, 3-(2-aminoethyl)-5-methoxyindole and 5-hydroxyacetyl-tryptamine.
GB33039/74A 1973-12-31 1974-12-31 Pharmaceutical product for treatment of all leukaemia forms and neurotic syndromes Expired GB1493941A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT4011573 1973-12-31

Publications (1)

Publication Number Publication Date
GB1493941A true GB1493941A (en) 1977-11-30

Family

ID=11248376

Family Applications (1)

Application Number Title Priority Date Filing Date
GB33039/74A Expired GB1493941A (en) 1973-12-31 1974-12-31 Pharmaceutical product for treatment of all leukaemia forms and neurotic syndromes

Country Status (10)

Country Link
JP (1) JPS5096565A (en)
AT (1) ATA617674A (en)
AU (1) AU7194974A (en)
BE (1) BE824022A (en)
CH (1) CH625218A5 (en)
DE (1) DE2435365A1 (en)
FR (1) FR2255897A1 (en)
GB (1) GB1493941A (en)
NL (1) NL7417046A (en)
ZA (1) ZA748264B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004659A1 (en) * 1987-11-19 1989-06-01 Cellena (Cell Engineering) A.G. Use of melatonin or derivatives thereof for the production of pharmaceutical compositions effective to counteract the effects of aging

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4506080A (en) * 1983-07-01 1985-03-19 Nestec S. A. Preparation of serotonine and derivatives
GR900100024A (en) * 1989-01-17 1991-06-07 Amr Int Method of treating pre-menstual syndrome
IT1243193B (en) * 1990-08-10 1994-05-24 Medea Res Srl ORAL PHARMACEUTICAL COMPOSITIONS BASED ON MELATONIN

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004659A1 (en) * 1987-11-19 1989-06-01 Cellena (Cell Engineering) A.G. Use of melatonin or derivatives thereof for the production of pharmaceutical compositions effective to counteract the effects of aging

Also Published As

Publication number Publication date
DE2435365A1 (en) 1976-01-29
NL7417046A (en) 1975-07-02
ZA748264B (en) 1976-01-28
AU7194974A (en) 1976-02-05
ATA617674A (en) 1976-11-15
FR2255897A1 (en) 1975-07-25
JPS5096565A (en) 1975-07-31
BE824022A (en) 1975-04-16
CH625218A5 (en) 1981-09-15

Similar Documents

Publication Publication Date Title
GB1493941A (en) Pharmaceutical product for treatment of all leukaemia forms and neurotic syndromes
McKillop et al. Acetoxythallation-induced lactonization of 2-endo-norbornenecarboxylic acids
SE7413652L (en)
JPS5265226A (en) Preparation of halogenosilanes
ES450350A1 (en) Perfume based on glycosyloxy derivatives and said scenttcontained smoking material and method of preparation of perfume based on glycosyloxy derivatives
CH608785A5 (en) Process for producing new N-acylglutamines
ES412246A1 (en) Hair shampoos
GB1538775A (en) Preparation of 6,11-dihydro-11-oxodibenz(b,e)-oxepin-alkanoic acids
GB983492A (en) Novel dilactones
SU700191A1 (en) Coating composition for containers of high-pressure and high-temperature apparatus
GB1399065A (en) Process for the production of tetrabromophthalic anhydride
ES433940A1 (en) Process for the preparation of 7-oxo-7h-dibenzo-(d e,h)-quinolin-2-ol
ES390243A1 (en) Phenanthrotriazolyl derivatives
ES406542A1 (en) Derivatives of 22-fluoro-digoxins
ES403938A1 (en) Cyclic decapeptides comprising an l-tyrosine radical
JPS51121597A (en) Process for producing tryptophan and its derivatives
GB1467225A (en) 7-alkoxy-4,6-dihydroxy-quinoline derivatives and pharmaceuti cal compositions thereof
JPS5626859A (en) Alpha-halogeno-beta-aminopropionitrile
ES452753A1 (en) Procedure for the preparation of sulfametoxazol-lysine salt. (Machine-translation by Google Translate, not legally binding)
ES424847A1 (en) Monoazo pigment and process for its manufacture
AU494291B2 (en) Conversion of modified synthesis gas to oxygenated organic chemicals
ES406790A1 (en) Alumina
GB1228303A (en)
ES447297A1 (en) Process for the preparation of N-acetoacetyl-2,5-dimethoxy-4-chloroanilide
ES431523A1 (en) A procedure for preparing a derivative of ftalazone. (Machine-translation by Google Translate, not legally binding)

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee